CRMD (CorMedix Inc.) stock: $5.32, $414.7M market cap, $256.7M cash, $158.0M EV, $523.5M fully diluted market cap. Next expected readout: Jan-28. Lead program: (taurolidine and heparin) catheter lock solution (Catheter-Related Infections), Phase 4. Data from Fully Diluted's biotech stocks database.
What they do
Our primary focus has been commercializing DefenCath® (taurolidine and heparin), in the U.S., which we launched in 2024 in the hemodialysis setting. The name DefenCath is the U.S. proprietary name approved by the U.S. Food and Drug Administration (“FDA”).
Estimated readout windows: registry primary-completion date + 6-12 weeks. Windows already open are shown from "Now". Drug names link to ClinicalTrials.gov.
Hemodialysis (inpatient and outpatient settings)(Approved)
Status note Taurolidine and heparin; launched commercially in the U.S. in 2024. BARDA government contract in place (product not specified in excerpts).
REZZAYO
Approved · Active
Aliases rezafungin for injection
Partnerships Melinta Therapeutics: acquired by CorMedix Aug 29, 2025 ($453.7M); U.S. commercialization rights; Napp/Mundipharma: acquired global REZZAYO rights from Cidara (Apr 2024); $30-40M regulatory milestone on marketing approval for the prophylaxis indication
Indications
Candidemia and invasive candidiasis (adults)(Approved)
Prophylaxis of invasive fungal diseases in allogeneic BMT/HSCT (adults)(Phase 3)
Catalysts
— 2027
Status note Approved for candidemia and invasive candidiasis in adults. Positive Phase III topline from ReSPECT (prophylaxis of invasive fungal diseases in allogeneic BMT/HSCT) announced Apr 27, 2026; commercialization in the second indication targeted from 2027 if FDA-approved.
MINOCIN IV
Approved · Active
Indications
Acinetobacter infections(Approved)
Status note Acquired via Melinta; one of few agents approved for Acinetobacter species.
Per-asset detail extracted from the 10-Q filed 2026-08-13. Fields the filing does not state are marked "not disclosed" rather than filled from other sources.
Central Line Associated Blood Stream Infections (CLABSI)
—
Sponsor-matched active trials from ClinicalTrials.gov (2 as sponsor, 0 as collaborator); "Sponsor" = company is the lead sponsor, "Collaborator" = company is a collaborator. The BP column flags big-pharma involvement as lead sponsor or collaborator (excluding the company itself). The Mgmt guide column shows what management guided for readout timing when a guided program matches the trial (hover for the quote, click for the source). Trial listings are not a company pipeline slide.